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Abstract
Background: With advancements in cancer treatment, the life expectancy of oncology patients has improved. Thus,
transcatheter aortic valve replacement (TAVR) may be considered as a feasible option for oncology patients with
severe symptomatic aortic stenosis (AS). We aim to evaluate the difference in short- and long-term all-cause mortality
in cancer and non-cancer patients treated with TAVR for severe AS.
Methods: Medline, PubMed, and Cochrane Central Register of Controlled Trials were searched for relevant studies.
Patients with cancer who underwent treatment with TAVR for severe AS were included and compared to an identical
population without cancer. The primary endpoints were short- and long-term all-cause mortality.
Results: Of 899 studies included, 8 met inclusion criteria. Cancer patients had significantly higher long-term allcause mortality after TAVR when compared to patients without cancer (risk ratio [RR] 1.43; 95% confidence interval
(CI) 1.26–1.62; P < 0.01). Four studies evaluated short-term mortality after TAVR and demonstrated no difference in it in
patients with and without cancer (RR 0.72; 95% CI 0.47–1.08; P = 0.11).
Conclusion: Patients with cancer and severe AS have higher long-term all-cause mortality after TAVR. However, we
found no difference in short-term all-cause mortality when comparing patients with and without cancer. The decision
to perform TAVR in cancer patients should be individualized based on life expectancy and existing co-morbidities.
Introduction
Due to the lower risk of complications, transcatheter aortic valve replacement (TAVR) has become the treatment
of choice over surgical aortic valve replacement (SAVR)
for frail patients with symptomatic aortic stenosis (AS)
[1]. The incidence of AS and cancer increases with age.
Twenty six percent of patients with AS have a history
of cancer or have active cancer [2, 3]. The increased
*Correspondence: Muhammad.siddiqui@jefferson.edu
1
Department of Internal Medicine, Thomas Jefferson University Hospitals,
833 Chestnut Street, Suite 701, Philadelphia, PA 19107, USA
Full list of author information is available at the end of the article

incidence of both AS and cancer with age is expected due
to shared risk factors related to cancer, cardiovascular
disease, and the pathophysiology behind degenerative AS
[4, 5]. It is known that radiotherapy, particularly mediastinal radiation for lymphoma, is associated with progressive aortic disease [6]. Concomitant chemotherapy, such
as with anthracyclines, can further increase the incidence
of AS [7]. Studies have shown that such therapy causes
AS by inducing valvular degeneration [8]. Since cancer
patients are at greater risk of developing AS, investigating
TAVR outcomes in this population becomes crucial.
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TAVR has been proven to improve the hemodynamics
and functional status of patients with severe symptomatic
AS [9–11]. Its widespread use has grown significantly. At
the same time, the life expectancy of cancer patients has
improved with advances in cancer therapy. As life expectancy increases in cancer patients, the presence of severe
symptomatic AS may impact prognosis to a greater
extent than that of many cancers. There have been limited studies that assess the mortality of cancer patients
with AS after TAVR. Two previous meta-analyses on
this topic were limited in scope and did not include all
the available evidence in their pooled outcomes. Thus, we
aim to comprehensively investigate the utility of TAVR in
cancer patients with severe AS.

Methods
Data sources and search strategy

This systematic review and meta-analysis was reported
according to Preferred Reporting Items for Systematic
Review and Meta-Analyses (PRISMA) guidelines [12].
Medline, PubMed, and Cochrane Central Register of
Controlled Trials were searched from database inception
through December 2020 using the following combination of keywords: transcatheter aortic valve replacement
OR transcatheter aortic valve implantation OR heart
valve prosthesis AND mortality OR short-term mortality OR long-term mortality AND malignancy OR cancer
OR neoplasms. No time restriction was placed on the
search. However, language was restricted to English. To
identify grey literature, online libraries including www.
clinicaltrialresults.org, www.clinicaltrials.gov, and presentations from major cardiovascular proceedings were
also searched. All citations retrieved from the search
were transferred to EndNote X7.5 Reference Manager
(Thompson ISI ResearchSoft, Philadelphia, Pennsylvania)
and duplicates were removed.
Study selection

All citations were screened by two independent reviewers (MUS and OY) on the basis of eligibility criteria.
Inclusion criteria in the included studies comprised of
adults with a diagnosis of cancer identified to have severe
AS and underwent treatment with TAVR. Patients in
whom TAVR was contraindicated or did not have TAVR
performed and patients who had SAVR for treatment
of severe AS were excluded. Studies that did not compare TAVR outcomes in patients without a history of
active cancer were excluded. The primary endpoint in
the included studies comprised of short- and long-term
all-cause mortality. Short-term mortality was defined
as death within 30 days after TAVR. Long-term mortality was defined as death 30 days after TAVR. Secondary
analyses were performed to identify the risk of cardiac
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mortality, myocardial infarction (MI), stroke, acute kidney injury (AKI), and major bleeding among patients
with and without cancer after TAVR.
Data extraction

Two independent reviewers (MUS and OY) extracted the
data on year of publication, study design, inclusion criteria, primary endpoints, type of cancer, and follow-up
time using a standardized data extraction form.
Statistical analysis

Outcomes from each study were pooled and compared
using a random effects model to account for potential
between study variances. Treatment effect was reported
as risk ratio (RR) and was supplemented by 95% confidence intervals (CI). The I2-statistic was quantified to
measure heterogeneity with values > 25%, 50%, and 75%
consistent with low, moderate, and high degrees of heterogeneity, respectively [13]. Review Manager Software
v5.41 was used for the analysis. A funnel plot was used
to assess for publication bias. P-values less than 0.05
were considered statistically significant. Certainty in
the evidence (i.e., confidence in the final estimates), was
assessed using the GRADE approach (Grades of Recommendation, Assessment, Development, and Evaluation) based on the risk of bias, imprecision, indirectness,
inconsistency, and publication bias.
Quality assessment of the included studies

Risk of bias was assessed using the Modified Newcastle–
Ottawa scale for observational studies, which assesses 3
domains: patient selection, comparability, and outcome
assessment (Additional file 1: Table S1) [14]. The methodological quality of a study was graded as high or low
based on whether the study had adequate adjustment
for confounders, which we judged to be the most critical
domain affecting the main outcomes of interest [15].

Results
Baseline demographics

After exclusion of duplicate and irrelevant items, the
initial search resulted in 899 articles. Eight studies
with a total of 12,165 patients met inclusion criteria
for quantitative analysis (Fig. 1) [16–23]. All the studies included were observational. The baseline characteristics of the included studies are shown in Table 1.
Mean age ranged between 79 and 83 in the cancer
group and 81–85 in the non-cancer group (Additional
file 1: Table S2). The mean follow-up time period was
2.4 years. Both solid and hematologic malignancies
were included in the studies. Transfemoral access
was the most common approach utilized for TAVR.
Bleiziffer et al. and Tabata et al. did not report the
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Fig. 1 The preferred reporting items for systematic reviews and meta-analyses (PRISMA) flow diagram of the included studies

approach utilized for TAVR, while Mangner et al.
included only patients who underwent TAVR with a
transfemoral approach. The remaining studies included
TAVR procedures utilizing transapical, transaxillary,
and transiliac approaches [16–18, 20]. The prospective
study conducted by Watanabe et al. used only balloonexpandable valves, whereas the study performed by
Landes et al. and Bleiziffer et al. utilized self-expandable valves. Biancari et al. did not report the type of
valve utilized for TAVR. The study conducted by Watanabe et al. and Landes et al. included patients with only
active cancer, while Berkovitch et al., Bleiziffer et al.
and Nuis et al. included patients only with past malignancy. In contrast, Mangner et al. and Biancari et al.

included patients with both active and past cancer.
Outcome data from the included studies are summarized in Additional file 1: Table S3.
Short‑term all‑cause mortality

Four studies reported short-term all-cause mortality
associated with TAVR in patients with cancer [17–19,
21]. The data for meta-analysis was pooled from these
studies. The risk of short-term mortality was not significantly different among TAVR patients with and without cancer (RR 0.72; 95% CI 0.47–1.08; Fig. 2). Very
little variation was noted between the trials as indicated
by low I2 value of 17%.

Prospective adjusted Patients who
non-randomized
underwent TAVR
trial
for symptomatic
severe AS

Observational
adjusted study

Observational
cohort study

Bleiziffer, 2017

Nuis, 2013

Tabata, 2020

All-cause mortality

Mortality

MACE

All-cause mortality, cardiovascular
mortality

All-cause mortality

All-cause mortality

Post-procedural
outcomes

All-cause mortality

Primary endpoint

1 year

Mean 2.4 years

Mean 2.1 years

2.3 years

1 year

Solid (predominantly 5 years
breast, prostate, and
colon cancer) and
hematologic

NR

NR

Solid and hematologic

Solid and hematologic

Solid (gastrointestinal, prostate, breast,
lung, renal, bladder)
and hematologic

Solid (lung, prostate, 2 years
breast, colon, liver,
head and neck,
gastric, pancreatic,
renal, bladder,
thyroid, brain) and
hematologic

NR

Transfemoral,
transapical,
transsubclavian,
transaortic

NR

Transapical

Exclusion criteria

Self-expandable

Edwards Sapien

Patients with missing
baseline hemoglobin

Enrollment in another
trial or inability to give
informed consent

NR

Self-expandable and NR
balloon-expandable

Medtronic CoreValve, Edwards
Sapien, Direct Flow
Valve

Medtronic CoreValve

NR

NR

NR

Bicuspid aortic valve,
failed SAVR, severe AR
and dialysis dependence

Self-expandable and NR
balloon-expandable

Valve type

Transfemoral,
Medtronic Cortransapical, transaxil- eValve and Edwards
lary
Sapien

Transfemoral

Transfemoral, transiliac, transapical

Transfemoral

Follow-up duration TAVR approach

Solid (predomi3 years
nantly breast and
prostate cancer) and
hematologic

Type of cancer

TAVR, transcatheter aortic valve replacement; NR, not reported; AS, aortic stenosis; SAVR, surgical aortic valve replacement; AR, aortic regurgitation; MACE, major adverse cardiovascular events

Patients who
underwent TAVR
for symptomatic
severe AS

Patients who
underwent TAVR
for symptomatic
severe AS

Patients who
underwent TAVR
for symptomatic
severe AS

Patients with active
cancer who underwent TAVR

Retrospective study

Prospective nonrandomized trial

Landes, 2019

Patients who
underwent TAVR
for symptomatic
severe AS

Biancari, 2020

Prospective nonrandomized trial

Watanabe, 2016

Patients with active
cancer, history of
cancer and without
cancer who underwent TAVR

Patients who
underwent TAVR
for symptomatic
severe AS

Prospective nonrandomized trial

Mangner, 2018

Inclusion criteria

Berkovitch, 2018 Prospective nonrandomized trial

Study design

Author, year

Table 1 Baseline characteristics of the included studies
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Fig. 2 Forest plot for short-term mortality comparing patients with and without cancer who underwent TAVR. Legend: The pooled risk ratio with
95% confidence intervals were calculated using a random effects model. Weight refers to the contribution of each study to the pooled estimate.
Squares and horizontal lines denote the point estimate and 95% confidence interval for each study’s risk ratio. The diamond signifies the pooled risk
ratio; the diamond center denotes the point estimate and the width denotes the 95% confidence interval

Long‑term all‑cause mortality

Eight studies reported long-term mortality associated
with TAVR in patients with cancer [17–23]. Pooled
results of these studies identified significantly higher risk
of long-term mortality among TAVR patients with cancer
when compared to patients without cancer (RR 1.43; 95%
CI 1.26–1.62; Fig. 3). Low level of variation was noted
between the trials in the primary analysis as indicated by
I2 values of 42%.
Sensitivity and subgroup analyses

Sensitivity analyses of long term all-cause mortality
was performed to identify if the trend was similar to
the overall result. For this purpose, the included studies
were organized into unadjusted and adjusted studies.
The sensitivity analysis identified that the difference in
long term all-cause mortality remained statistically significant in both unadjusted (RR 1.68, 95% CI 1.26–2.25)
and adjusted (RR 1.35, 95% CI 1.18–1.55) subgroups
similar to the overall result (Additional file 1: Figure

S1). For subgroup analysis, the study population was
organized into no cancer (NC) (control group), active
cancer (AC), and past cancer (PC) groups. Similar to
the pooled result, there was no difference in short-term
mortality among patients with AC and NC. However,
there was significantly higher risk of short-term mortality in the NC group when compared to the PC group
(Additional file 1: Figure S2). This contrasting result
was likely due to the small sample size and increased
confounding in the unadjusted studies. Similar to the
pooled result, there was significantly higher risk of
long-term mortality in patient with AC and PC when
compared to NC (Additional file 1: Figure S3). Further
subgroup analysis was performed for long term mortality by classifying the studies into those with follow-up
of 2 years or less and follow-up of greater than 2 years.
Both the groups showed increased risk of long term
mortality among cancer patients (RR 1.72; 95% CI
1.37–2.15 and RR 1.35; 95% CI 1.19–1.53) (Additional
file 1: Figure S4).

Fig. 3 Forest plot for long-term mortality comparing patients with and without cancer who underwent TAVR. Legend: The pooled risk ratio with
95% confidence intervals were calculated using a random effects model. Weight refers to the contribution of each study to the pooled estimate.
Squares and horizontal lines denote the point estimate and 95% confidence interval for each study’s risk ratio. The diamond signifies the pooled risk
ratio; the diamond center denotes the point estimate and the width denotes the 95% confidence interval
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Leave one out analysis

After removing the study performed by Landes et al.
which included subjects with only active cancer, the
result for long term mortality remained similar to the
overall pooled result (RR 1.37; 95% CI 1.25–1.51). However, the heterogeneity decreased (I2 = 15%) (Additional
file 1: Figure S5).
Secondary endpoints

The results from included studies were pooled where
data was available to identify the risk of secondary endpoints. There was no difference in long term cardiac mortality (RR 0.87, 95% CI 0.71–1.06), MI (RR 1.20, 95% CI
0.37–2.89), stroke (RR 0.89, 95% CI 0.59–1.35), AKI (RR
0.92, 95% CI 0.66–1.30), or major bleeding (RR 1.26, 95%
CI 0.70–2.28) between patients with and without cancer
who underwent TAVR (Additional file 1: Figures S6 and
S7).
Certainty in the estimates

The included studies were observational with variable
methodological quality and thus are at increased risk of
selection and confounding bias. The estimates were precise for short term mortality, long term mortality, and all
the secondary endpoints except for MI which had less
than 100 events. There was no indirectness or evidence
of publication bias. Heterogeneity was noted among the
included studies. The quantified I 2 value for each individual primary outcomes investigated in this meta-analysis
are as follows: short term mortality 17% (minimal) and
long term mortality 42% (low). The I2 value for secondary
outcomes ranged from 0 to 83%. Overall, the certainty in
the estimates in all the outcomes was judged to be moderate. Additional file 1: Figure S8 demonstrates a funnel
plot to assess for publication bias in the studies reporting
long-term mortality.

Discussion
We investigated the short- and long-term all-cause mortality in patients undergoing TAVR for AS with underlying malignancy compared to those without. There was
no difference in short-term mortality among patients
with cancer compared to those without who underwent
TAVR. However, patients with malignancy had increased
long-term all-cause mortality after TAVR. Subgroup
analyses demonstrated that the higher risk of all-cause
long-term mortality was apparent in those with active
and past cancer. No significant difference was noted
in the secondary endpoints between groups, including
long-term cardiac mortality.
Our analysis differs from two previous meta-analyses
published on this topic. The meta-analysis performed by
Murphy et al. included studies that exclusively enrolled
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patients who received thoracic irradiation for cancer treatment [24]. These patients are expected to have
higher cardiovascular complications, including constrictive pericarditis, coronary artery disease, conduction
abnormalities, and valvular abnormalities when compared to chemotherapy related cardiac dysfunction [25].
Murphy et al. also did not include the studies performed
by Landes, Biancari, and Watanabe et al. in their pooled
analysis. In contrast to our study, Murphy et al. did not
find a difference in long-term all-cause mortality in
patients with and without cancer who underwent TAVR.
Bendary et al. also performed a meta-analysis looking at
mortality outcomes in cancer patients with TAVR [26].
However, the pooled analysis only included three studies and subgroup analysis was not performed to identify
differences in outcomes comparing patients with active
versus past cancer. The pooled results for short- and long
term all-cause mortality was similar to our study.
The introduction of TAVR has allowed physicians
to treat many patients with AS in whom aortic valve
replacement (AVR) was initially thought to be contraindicated. Namely due to the risks and potential complications associated with open surgery. Severe symptomatic
AS has a prognosis that is worse than many cancers with
respect to both morbidity and mortality. The prognosis and expected length of survival is further worsened
when patients with severe AS also have comorbid cancer.
This raises the question whether these patients who have
malignancy along with severe AS should be offered AVR.
The treatment of cancer, which includes oncologic surgery, chemotherapy, or radiation therapy, might lead to
worsening of aortic valve disease, either because of effects
on the valve or on myocardial function. In turn, this may
result in withholding effective cancer therapy in patients
suffering from severe AS. The European Society of Cardiology recommends afterload reduction with medical therapy in patients with left ventricle dysfunction or
heart failure induced by anthracycline or antineoplastic therapy [27]. The most effective afterload reduction
strategy in patients with AS is treatment of the stenotic
valve, which can be through TAVR, SAVR, or balloon
valvuloplasty. It has been observed that balloon valvuloplasty fails to improve survival in patients with AS,
rather, it is associated with increased complications and
higher restenosis rates [28, 29]. SAVR is usually decided
on a case by case basis, but in patients with malignancy,
concerns regarding important complications exist. Cancer patients undergoing SAVR may be at increased risk of
infection due to immunosuppression, while cachexia may
impact recovery and mediastinal fusion. Cancer patients
are often anemic, have low platelet counts, and have clotting abnormalities [30]. This places them at higher risk
of bleeding complications, particularly those placed on
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cardio-pulmonary bypass [31, 32]. Thus, the invasive
nature of SAVR renders it less desirable in this patient
population. TAVR might be the optimal strategy for the
treatment of select oncology patients, as it minimizes the
concerns associated with surgery, including with regards
to its invasiveness, increased risk of bleeding, infections,
and the suspension of oncological treatment after surgery
during recovery [30–34].
Our study agrees with the findings from Mangner
et al., Nuis et al., and Bleiziffer et al., who reported that
malignancy was associated with increased odds of longterm mortality post TAVR. This is in contrast to the prospective studies by Watanabe et al. and Biancari et al.,
where they showed no difference in long-term mortality
in patients with or without malignancy post-TAVR. We
believe that this difference is likely due to the variability
in cancer type and stage, duration of treatment, and ejection fraction (EF) in the population studied. It is important to recognize that long-term mortality post-TAVR
is unlikely to be related to the TAVR procedure itself,
but more likely to be driven by underlying pre-existing
comorbidities. Participants included in the trial conducted by Watanabe et al. had a higher mean EF in both
cancer and non-cancer groups compared to the study
conducted by Mangner et al. Berkovitch et al. reported
that patients with malignancy who underwent cancer
related treatment < 1 year ago had a higher long-term
mortality after TAVR [18]. Thus, this suggests that cancer activity significantly impacted patient survival. Further studies would be useful to clarify the role of cancer
type and cancer stage on morbidity and mortality postTAVR. Indeed, the 2021 European Society of Cardiology
and the European Association for Cardiothoracic Surgery
guidelines for the management of valvular heart disease
recommends early intervention in those with symptomatic severe AS, except for those in whom intervention
is unlikely to improve quality of life or survival or for
those with concomitant conditions associated with survival < 1 year (e.g. malignancy).
We found no difference in periprocedural complications in patients with and without cancer after TAVR.
Despite this, it is important to be conscious that performing TAVR in patients with cancer is still high-risk.
These patients are at greater risk of cardiopulmonary
dysfunction from prior chemoradiotherapy. Additionally, they are at increased risk of significant aortic valve
and annular calcification. This makes treatment with selfexpanding prostheses challenging due to under-expansion, which places patients at higher odds of paravalvular
regurgitation [35, 36].
This meta-analysis has limitations primarily due to limitations in the studies that were included. The studies are
non-randomized, introducing the possibility of selection
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and sample biases. There was a difference in baseline
characteristics, including baseline cardiac function,
malignancy type, TAVR approach, valve type and followup duration, which introduces heterogeneity. This limitation was reduced by performing subgroup and leave one
out analyses. Meta-regression could not be performed
due to the number of studies being less than 10. As the
studies were not blinded, a moderate risk of performance
bias was observed among the included studies. Finally,
we restricted this study to include articles from PubMed
and Cochrane databases. Hence, it is possible that there
are other studies matching our inclusion criteria that are
not included in our meta-analysis.

Conclusion
This study offers insight into the mortality among cancer
patients who undergo TAVR. Our meta-analysis identified higher risk of long-term all-cause mortality among
patients with active and past cancer who undergo TAVR.
The increased mortality is likely multifactorial and could
be related to cancer stage, cancer type, chemotherapy
utilized, and pre-existing co-morbidities. There was no
difference in short-term mortality, cardiac mortality, or
periprocedural complications between cancer and noncancer patients who undergo TAVR. A multidisciplinary approach, including with oncologists and cardiac
surgeons, is required to create a comprehensive plan for
cancer patients being considered for TAVR. The decision to undergo TAVR in this population should always
be individualized after contemplating the risks associated
with the procedure as well as complications that could
arise due to cancer.
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